Jun 13 |
Insider Sale: Director Matthew Posard Sells Shares of Halozyme Therapeutics Inc (HALO)
|
Jun 12 |
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
|
Jun 11 |
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded by Piper Sandler
|
Jun 11 |
Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?
|
Jun 9 |
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
|
Jun 7 |
Halozyme Therapeutics Scores RS Rating Jump To 91
|
Jun 7 |
Halozyme Therapeutics: The Story Brightens
|
Jun 7 |
Halozyme downgraded at Piper Sandler despite guidance raise
|
Jun 7 |
Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%
|
Jun 6 |
Halozyme hits 52-week high as patent win prompts guidance raise
|